CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Adenine
/ analogs & derivatives
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Humans
Male
Middle Aged
Mutation
Neoplasm Proteins
/ genetics
Piperidines
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Receptors, CXCR4
/ genetics
Survival Rate
Waldenstrom Macroglobulinemia
/ drug therapy
CXCR4
Waldenström macroglobulinaemia
ibrutinib
response
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
23
03
2019
accepted:
21
05
2019
pubmed:
4
7
2019
medline:
17
6
2020
entrez:
4
7
2019
Statut:
ppublish
Résumé
Ibrutinib is associated with response rate of 90% and median progression-free survival (PFS) in excess of 5 years in Waldenström macroglobulinaemia (WM) patients. CXCR4 mutations are detected in 30-40% of patients with WM and associate with lower rates of response and shorter PFS to ibrutinib therapy. Both frameshift (CXCR4
Substances chimiques
CXCR4 protein, human
0
Neoplasm Proteins
0
Piperidines
0
Pyrazoles
0
Pyrimidines
0
Receptors, CXCR4
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-363Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Busillo, J.M. & Benovic, J.L. (2007) Regulation of CXCR1 signaling. Biochimica et Biophysica Acta, 1768, 952-963.
Buske, C., Tedeschi, A., Trotman, J., García-Sanz, R., MacDonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C.S., Palomba, M.L., Matous, J.V., Shustik, C., Kastritis, E., Treon, S.P., Lih, C.-J., Li, J., Salman, Z., Graef, T. & Dimopoulos, M.A. (2018) Ibrutinib treatment in waldenström's macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood, 132, 149.
Cao, Y., Hunter, Z.R., Liu, X., Xu, L., Yang, G., Chen, J., Tsakmaklis, N., Kanan, S., Castillo, J.J. & Treon, S.P. (2015a) CXCR3 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells. British Journal of Haematology, 168, 701-707.
Cao, Y., Hunter, Z.R., Liu, X., Xu, L., Yang, G., Chen, J., Patterson, C.J., Tsakmaklis, N., Kanan, S., Rodig, S., Castillo, J.J. & Treon, S.P. (2015b) The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia, 29, 169-176.
Castillo, J.J., Gustine, J.N., Meid, K., Dubeau, T., Severns, P., Xu, L., Yang, G., Hunter, Z.R. & Treon, S.P. (2018a) Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstrom macroglobulinaemia. British Journal of Haematology, 184, 1011-1014.
Castillo, J.J., Meid, K., Gustine, J.N., Dubeau, T., Severns, P., Hunter, Z.R., Yang, G., Xu, L. & Treon, S.P. (2018b) Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia. Clinical Cancer Research, 24, 3247-3252.
Dimopoulos, M.A., Trotman, J., Tedeschi, A., Matous, J.V., Macdonald, D., Tam, C., Tournilhac, O., Ma, S., Oriol, A., Heffner, L.T., Shustik, C., Garcia-Sanz, R., Cornell, R.F., deLarrea, C.F., Castillo, J.J., Granell, M., Kyrtsonis, M.C., Leblond, V., Symeonidis, A., Kastritis, E., Singh, P., Li, J., Graef, T., Bilotti, E., Treon, S., Buske, C., iNnovate Study Group & the European Consortium for Waldenstrom's Macroglobulinemia (2017) Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology, 18, 241-250.
Dimopoulos, M.A., Tedeschi, A., Trotman, J., Garcia-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., Palomba, M.L., Matous, J.V., Shustik, C., Kastritis, E., Treon, S.P., Li, J., Salman, Z., Graef, T., Buske, C., iNnovate Study Group & the European Consortium for Waldenstrom's Macroglobulinemia (2018) Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. New England Journal of Medicine, 378, 2399-2410.
Dotta, L., Tassone, L. & Badolato, R. (2011) Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Current Molecular Medicine, 11, 317-325.
Gustine, J.N., Meid, K., Dubeau, T., Hunter, Z.R., Xu, L., Yang, G., Ghobrial, I.M., Treon, S.P. & Castillo, J.J. (2017) Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia. British Journal of Haematology, 177, 717-725.
Hunter, Z.R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R.J., Tripsas, C., Patterson, C.J., Sheehy, P. & Treon, S.P. (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR12 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 123, 1637-1646.
Hunter, Z.R., Yang, G., Xu, L., Liu, X., Castillo, J.J. & Treon, S.P. (2017) Genomics, signaling, and treatment of Waldenstrom macroglobulinemia. Journal of Clinical Oncology, 35, 994-1001.
Kyle, R.A., Treon, S.P., Alexanian, R., Barlogie, B., Bjorkholm, M., Dhodapkar, M., Lister, T.A., Merlini, G., Morel, P., Stone, M., Branagan, A.R. & Leblond, V. (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 116-120.
Olszewski, A.J., Treon, S.P. & Castillo, J.J. (2016) Evolution of management and outcomes in Waldenstrom macroglobulinemia: a population-based analysis. The Oncologist, 21, 1377-1386.
Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 110-115.
Owen, R.G., Kyle, R.A., Stone, M.J., Rawstron, A.C., Leblond, V., Merlini, G., Garcia-Sanz, R., Ocio, E.M., Morra, E., Morel, P., Anderson, K.C., Patterson, C.J., Munshi, N.C., Tedeschi, A., Joshua, D.E., Kastritis, E., Terpos, E., Ghobrial, I.M., Leleu, X., Gertz, M.A., Ansell, S.M., Morice, W.G., Kimby, E. & Treon, S.P. (2013) Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. British Journal of Haematology, 160, 171-176.
Poulain, S., Roumier, C., Venet-Caillault, A., Figeac, M., Herbaux, C., Marot, G., Doye, E., Bertrand, E., Geffroy, S., Lepretre, F., Nibourel, O., Decambron, A., Boyle, E.M., Renneville, A., Tricot, S., Daudignon, A., Quesnel, B., Duthilleul, P., Preudhomme, C. & Leleu, X. (2016) Genomic landscape of CXCR18 mutations in Waldenstrom macroglobulinemia. Clinical Cancer Research, 22, 1480-1488.
Roccaro, A.M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., Cohen, L., San Miguel, J.F., Garcia-Sanz, R. & Ghobrial, I.M. (2014) C1013G/CXCR19 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 123, 4120-4131.
de Rooij, M.F., Kuil, A., Kraan, W., Kersten, M.J., Treon, S.P., Pals, S.T. & Spaargaren, M. (2016) Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR7-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. Haematologica, 101, e111-115.
Schmidt, J., Federmann, B., Schindler, N., Steinhilber, J., Bonzheim, I., Fend, F. & Quintanilla-Martinez, L. (2015) MYD88 L265P and CXCR20 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. British Journal of Haematology, 169, 795-803.
Sklavenitis-Pistofidis, R., Capelletti, M., Liu, C.J., Reidy, M., Zavidij, O., Huynh, D., Henrick, P., Savell, A., Reyes, K., Rivotto, B., Bustoros, M., Perilla-Glen, A., Trippa, L., Castillo, J.J., Treon, S.P. & Ghobrial, I.M. (2018) Bortezomib overcomes the negative impact of CXCR21 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 132, 2608-2612.
Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R. (2012) MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. New England Journal of Medicine, 367, 826-833.
Treon, S.P., Cao, Y., Xu, L., Yang, G., Liu, X. & Hunter, Z.R. (2014a) Somatic mutations in MYD88 and CXCR23 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood, 123, 2791-2796.
Treon, S.P., Tripsas, C.K., Meid, K., Kanan, S., Sheehy, P., Chuma, S., Xu, L., Cao, Y., Yang, G., Liu, X., Patterson, C.J., Warren, D., Hunter, Z.R., Turnbull, B., Ghobrial, I.M. & Castillo, J.J. (2014b) Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia. Blood, 124, 503-510.
Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K.V., Yang, G., Cao, Y., Xu, L., Patterson, C.J., Rodig, S., Zehnder, J.L., Aster, J.C., Harris, N.L., Kanan, S., Ghobrial, I., Castillo, J.J., Laubach, J.P., Hunter, Z.R., Salman, Z., Li, J., Cheng, M., Clow, F., Graef, T., Palomba, M.L. & Advani, R.H. (2015a) Ibrutinib in previously treated Waldenstrom's macroglobulinemia. New England Journal of Medicine, 372, 1430-1440.
Treon, S.P., Xu, L. & Hunter, Z. (2015b) MYD88 Mutations and response to ibrutinib in Waldenstrom's macroglobulinemia. New England Journal of Medicine, 373, 584-586.
Treon, S.P., Gustine, J., Meid, K., Dubeau, T., Severns, P., Patterson, C.J., Xu, L., Yang, G., Liu, X., Demos, M., Kofides, A., Chen, J.J., Munshi, M., Tsakmaklis, N., Chan, G., Yee, A.J., Raje, N., O'Donnell, E., Hunter, Z.R. & Castillo, J.J. (2017a) Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom’s Macroglobulinemia. Blood, 130, 2767.
Treon, S.P., Meid, K., Gustine, J., Bantilan, K.S., Dubeau, T., Severns, P., Yang, G., Xu, L., Patterson, C., Ghobrial, I.M., Laubach, J., Hunter, Z., Castillo, J.J., Palomba, M.L. & Advani, R.H. (2017b) Long-term follow-up of previously treated patients who received ibrutinib for symptomatic Waldenstrom's macroglobulinemia: update of pivotal clinical trial. Blood, 130, 2766.
Xu, L., Hunter, Z.R., Yang, G., Zhou, Y., Cao, Y., Liu, X., Morra, E., Trojani, A., Greco, A., Arcaini, L., Varettoni, M., Brown, J.R., Tai, Y.T., Anderson, K.C., Munshi, N.C., Patterson, C.J., Manning, R.J., Tripsas, C.K., Lindeman, N.I. & Treon, S.P. (2013) MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood, 121, 2051-2058.
Xu, L., Hunter, Z.R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., Liu, X., Kanan, S., Castillo, J.J., Tai, Y.T., Zehnder, J.L., Brown, J.R., Carrasco, R.D., Advani, R., Sabile, J.M., Argyropoulos, K., Lia Palomba, M., Morra, E., Trojani, A., Greco, A., Tedeschi, A., Varettoni, M., Arcaini, L., Munshi, N.M., Anderson, K.C. & Treon, S.P. (2016) Clonal architecture of CXCR30 WHIM-like mutations in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 172, 735-744.
Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R.J., Patterson, C.J., Buhrlage, S.J., Gray, N., Tai, Y.T., Anderson, K.C., Hunter, Z.R. & Treon, S.P. (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood, 122, 1222-1232.